Results 201 to 210 of about 997,958 (247)

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

Screening of <i>Forsythia suspensa</i>-derived compounds identifies amentoflavone as a ciprofloxacin-potentiating candidate against MRSA. [PDF]

Front Microbiol
Fang Y, Yue T, Zhong J, Zheng H, Li F, Jiang L.   +5 more
europepmc   +1 more source

Quantitative Systems Toxicology Model Predicts Obeticholic Acid‐Associated Liver Injury in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Clinical Pharmacology &Therapeutics, EarlyView.
Obeticholic acid (OCA), a synthetic analog of chenodeoxycholic acid, was approved in 2016 for the treatment of primary biliary cholangitis. Early clinical trials revealed elevated liver biomarkers in healthy subjects receiving supratherapeutic OCA doses (100–250 mg).
Abigail K. Mayo, James J. Beaudoin, Jeffrey L. Woodhead, Paul B. Watkins, Kim L. R. Brouwer   +4 more
wiley   +1 more source

High resolution cryo-EM structure of the <i>Pseudomonas aeruginosa</i> OprM multidrug efflux pump provides target for rational inhibitor design. [PDF]

J Struct Biol X
Ratliff AC, Botos I, Putti AM, Patil PP, Ramkumar A, Ghirlando R, Dekker JP, Buchanan SK.   +7 more
europepmc   +1 more source

The Effect of Dicloxacillin Administration on Pharmacokinetics of Narrow Therapeutic Window Drugs: Phenytoin and Warfarin

Clinical Pharmacology &Therapeutics, EarlyView.
Dicloxacillin is a penicillinase‐resistant beta‐lactam antibiotic and potent activator of the Pregnane X receptor (PXR), known to induce CYP2C9, CYP2C19, and CYP3A4 activity. Clinical data suggest it reduces anticoagulation in warfarin‐treated patients and increases the risk of thromboembolic events.
Chanan Shaul, Waseem Mujahed, Ibrahim Idries, Maor Wanounou, Meir Bialer, Yoseph Caraco   +5 more
wiley   +1 more source

Pathogenesis and Triazole Resistance in <i>Aspergillus fumigatus</i>: A Narrative Review Across the Host Immune Spectrum and One Health Context. [PDF]

Infect Drug Resist
Chen T, Yao Y, Chen J, Lv H, Nan P.
europepmc   +1 more source

Integrated assessment of rifampicin‐mediated induction of transporters and drug‐metabolizing enzymes in a long‐term human liver tissue chip system

Clinical Pharmacology &Therapeutics, EarlyView.
Rifampicin is a prototypical clinical inducer used in drug–drug interaction (DDI) studies. However, the clinical relevance and predictability of rifampicin‐mediated hepatic transporter induction remain poorly defined. Conventional hepatocyte culture models fail to capture clinically relevant regulation of transporters and drug‐metabolizing enzymes ...
Mattie E. Hartauer, Raeanne M. Lanphier, Shivam Ohri, Jessica Snyder, Jacqueline B. Tiley, John K. Fallon, Henry Ho, Murat Cirit, Shiny Amala Priya Rajan, Kim L. R. Brouwer   +9 more
wiley   +1 more source

Plant-Derived Compounds as Antibiotic Adjuvants Against Drug-Resistant ESKAPE Pathogens: Mechanisms of Action, Synergistic Strategies, and Translational Challenges. [PDF]

Antibiotics (Basel)
Ruga S, Matarese E, Castagna F, Sansone C, Martinelli C, Mazzarotti G, Russo A, Medugno A, Shani S, Giordano A, Bava R, Liguori G.   +11 more
europepmc   +1 more source

Empirical PK/PD Model for Differentiating Intrinsic Dosing Rules by Therapeutic Indication With Relevance for HIV‐1 Latency Reversal

Clinical Pharmacology &Therapeutics, EarlyView.
Romidepsin (RMD), an FDA‐approved histone deacetylase inhibitor for treating cancer, demonstrates potent latency‐reversing activity in vitro but has yielded suboptimal outcomes in kick‐and‐kill HIV‐cure trials when administered as a 5 mg/m2 infusion.
Lauren A. R. Tompkins, Amanda Poliseno, Airlie Ward, Edward P. Browne, Cassandra Gilbert, Craig Sykes, Angela D. M. Kashuba, Mackenzie L. Cottrell   +7 more
wiley   +1 more source

Detection of carbapenem resistance mechanisms in difficult-to-treat Pseudomonas aeruginosa clinical isolates from a tertiary care hospital in Egypt. [PDF]

BMC Microbiol
Salem D, Zaiton M, El-Shenawy A, Dahroug H, El-Dein S, Gamal D, Althoqapy AA, Mohamed AA, Shemis MA, Diab M, Maklad SS.   +10 more
europepmc   +1 more source